Focus Partners Wealth
MDGL icon

Focus Partners Wealth’s Madrigal Pharmaceuticals MDGL Stock Holding History

Focus Partners Wealth’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.59M Buy
+8,541
New +$4.38M ﹤0.01% 1001
2024
Q3 		– Sell
-970
Closed -$272K – 1661
2024
Q2 		$272K Buy
+970
New +$231K ﹤0.01% 1095

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Focus Partners Wealth's MDGL Position: Q2 2026 in Review

Focus Partners Wealth opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 8,541 shares worth $4.59M. The stake represents ﹤0.01% of the portfolio and ranks #1001 among its holdings. This is a return to the name: Focus Partners Wealth previously reported a position in MDGL as recently as Q2 2024.

Focus Partners Wealth first reported a position in MDGL in Q2 2024 and has held it in 2 quarters since. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Focus Partners Wealth held 8,541 shares of Madrigal Pharmaceuticals worth $4.59M as of Q2 2026.
  • Madrigal Pharmaceuticals was a new Focus Partners Wealth position in Q2 2026.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #1001 holding.
  • Focus Partners Wealth first reported a position in Madrigal Pharmaceuticals in Q2 2024 and has held it in 2 quarters since.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.